ProRata.ai and DPCMO Sign LOI to Enhance Content Consent, Credit, and Compensation in the Age of Generative AI
ProRata.ai and The Danish Press Publications’ Collective Management Organisation (DPCMO) have signed a Letter of Intent to explore collaborative opportunities aimed at ensuring fair credit and compensation for the use of Danish media content in the era of generative AI. ProRata.ai, founded by Bill Gross, has developed a proprietary platform that analyzes AI-generated outputs, credits contributing content, and calculates proportional remuneration for content creators. The company's mission is to ensure that generative AI compensates and credits content owners for the use of their material.
DPCMO represents 99% of the Danish news industry and is approved by the Danish Ministry of Culture. The organization’s purpose is to ensure that tech companies benefiting from press publishers’ content contribute to the creative ecosystem transparently and accountably. By partnering with ProRata.ai, DPCMO aims to establish a framework where content creators in Denmark are duly recognized and compensated, fostering a sustainable and equitable digital content ecosystem.
Bill Gross, CEO of ProRata.ai, stated, "Our collaboration with DPCMO underscores our commitment to safeguarding the rights of content creators. By combining our attribution technology with DPCMO's extensive reach in Denmark, we aim to set a new standard for fairness, attribution, and transparency in the generative AI era."
Karen Rønde, CEO of DPCMO, added, "It is a great pleasure to engage with ProRata.ai, which acknowledges that human-made quality content has value. The enhancement of intellectual property rights since the Industrial Revolution has played a crucial role in encouraging innovation, fostering technological progress, and stimulating economic growth. We look forward to exploring business opportunities."
About ProRata.ai
Founded in 2024 by Bill Gross at Idealab Studio, ProRata’s mission is to ensure that generative AI compensates and credits content owners for the use of their material. ProRata builds technology that enables generative AI platforms to attribute contributing content sources and share revenues on a per-use basis, protecting and rewarding creators while helping to prevent unreliable content from compromising AI results. For more information, please visit prorata.ai.
About DPCMO
Founded in 2021, DPCMO is a collective rights management organisation representing Danish media companies and their press publishers neighbouring rights, text and data mining and AI rights. DPCMO represents a diverse circle of members; state-owned public service media, local, regional and national newspapers, magazines, special media, and digitals media outlets. A diverse and vibrant Danish media landscape is essential to democracy.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241125818129/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Special Seminar Paves the Way for European Dairy Brands to Enter China’s Special Food Market Under New Rules5.6.2025 04:50:00 CEST | Press release
CCIC Europe Food Test Co., Ltd. (CCIC EFT) is stepping up efforts to help more European companies access China’s infant formula market. On June 25–26, CCIC EFT will host a targeted seminar in Wageningen, the Netherlands, focused on regulatory updates and market access for producers of infant formula, older infant and toddler milk-based formula, and food for special medical purposes (FSMP). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250604444992/en/ CCIC Europe Food Test Co., Ltd. (CCIC EFT) and Technology Innovation Center of Special Food, State Administration of Market Regulation (TISF, SAMR) in the Netherlands. Co-organized with the Technology Innovation Center of Special Food, State Administration of Market Regulation (TISF, SAMR), the seminar is designed for professionals familiar with Chinese regulations and seeking the latest updates on standards, product registration, and market trends. Attendees will benefit from
Andersen Consulting annoncerer samarbejde med Bretteville Consulting5.6.2025 03:54:00 CEST | Pressemeddelelse
Andersen Consulting har indgået en samarbejdsaftale med Bretteville Consulting, der er et konsulentfirma inden for ledelse, som er kendt for sin dybe ekspertise inden for strategisk transformation og driftsoptimering, hvilket styrker Andersen Consultings globale platform med understøttende løsninger til kunder over hele verden. Bretteville Consulting, der blev grundlagt i Frankrig og har en tilstedeværelse i Kina, Singapore, Luxembourg og USA, tilbyder strategisk rådgivning, som hjælper organisationer med at styrke deres performance og accelerere deres transformation. Virksomheden specialiserer sig i implementering af virksomhedsstrategier, driftseffektivitet og forandringsledelse. I kraft af deres seniorstyrede konsulentmodel og en kundeorienteret tilgang har Bretteville opnået et solidt ry for at guide virksomheder gennem komplekse forretningsudfordringer og bæredygtige vækstinitiativer. Damien Gourio, der er administrerende direktør for Bretteville Consulting, udtaler: "Andersens gl
Belkin Unveils New Gaming Portfolio Featuring Power-Packed Charging Accessories and Gaming Essentials5.6.2025 01:00:00 CEST | Press release
Belkin’s first iteration of gaming accessories will feature products designed to be compatible with Nintendo Switch 2 Belkin, a leading consumer electronics brand for over 40 years, today announced its entry into the gaming accessories space with the launch of a new lineup designed to be compatible with the highly anticipated Nintendo Switch 2. Built on decades of experience in power, connectivity and device protection, and released under Belkin’s innovation-focused Future Ventures category, this marks the company’s first collection of products tailored specifically for the gaming community. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250604528148/en/ Belkin’s lineup of Nintendo Switch 2 accessories Belkin is “Leveling up your play” – bringing a new level of reliability to the gaming ecosystem that differentiates through premium materials, timeless design, and in-house engineering. The new range includes elevated accessor
Biocytogen and Nanjing Chia Tai Tianqing Announce IND Approval in China for Co-Developed Anti-IGF-1R Antibody NTB003 (BCG009)5.6.2025 01:00:00 CEST | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (“Biocytogen”, HKEX: 02315) and Nanjing Chia Tai Tianqing Pharmaceutical Co., Ltd. (“NJCTTQ”) announced that NTB003 (formerly BCG009), a co-developed injectable drug candidate, has received the Investigational New Drug (IND) approval from the National Medical Products Administration (NMPA). The approved indication is Thyroid Eye Disease (TED). About NTB003 Injection NTB003 is a second-generation fully human anti-IGF-1R monoclonal antibody co-developed by Biocytogen and Nanjing Chia Tai Tianqing. Antibody discovery and optimization were completed by Biocytogen using its proprietary RenMab™ fully human antibody discovery platform, while Nanjing Chia Tai Tianqing was responsible for CMC process development, GLP-compliant toxicology studies, and IND application. Compared with first-generation approved anti-IGF-1R therapeutics, NTB003 demonstrates enhanced molecular affinity, improved druggability, and an extended half-life. In vitro studies ha
New Potential Treatment Strategy for Brain Metastases and Leptomeningeal Disease: HER3-DXd Shows Promising Results in the Phase II TUXEDO-3 Study for Patients With Limited Therapeutic Options4.6.2025 20:19:00 CEST | Press release
The TUXEDO-3 trial is the first study to evaluate the intracranial and extracranial efficacy and safety of a novel anti-cancer drug in patients with breast and lung cancer and active brain metastases, and leptomeningeal disease from solid tumors. These results were presented as an oral presentation at the American Society of Clinical Oncology (ASCO) 2025 Annual Meeting, with select results simultaneously published in Nature Medicine. MEDSIR’s DEMETHER clinical trial was mentioned during abstract discussion due to the relevance of its strategy. Leading international medical research company, MEDSIR announced today the positive results of the TUXEDO-3 trial at the American Society of Clinical Oncology (ASCO) Annual Meeting 2025. This phase II study funded by Daiichi Sankyo and Merck, known as MSD outside of the United States and Canada, evaluates the efficacy and safety of patritumab deruxtecan (HER3-DXd) in patients with active brain metastases and leptomeningeal disease, serious compli
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom